Take-home message {#FPar12}
=================

Acute kidney injury (AKI) during SARS-CoV-2 infection is associated with high mortality rates in ICU. The pathophysiology of AKI currently relies on unspecific mechanisms (hypovolemia, nephrotoxic drugs, high PEEP, right heart failure), a direct viral injury, an imbalanced Renin-Angiotensin-Aldosterone System (RAAS) activation, an elevation of pro-inflammatory cytokines elicited by the viral infection, and a procoagulant state. To date, there is no specific treatment for COVID-19 induced AKI.

Introduction {#Sec1}
============

Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused an international outbreak of respiratory illness described as COVID-19. On the May 26, 2020, 5,404,512 confirmed cases of COVID-19 including 343,514 deaths were reported by The World Health Organization. Acute kidney injury (AKI) is a frequent condition in critically ill patients, in particular in those with serious infections, and has been associated with substantial morbidity and mortality \[[@CR1]\]. Since the onset of the new SARS-CoV-2 outbreak, several studies have focused on pulmonary complications, namely acute respiratory syndrome, which is the leading condition in intensive care unit (ICU) admission and associated with high mortality rate \[[@CR2]--[@CR5]\]. Initially little attention was paid to the AKI incidence in those patients, and kidney involvement was considered negligible \[[@CR6]\]. However, there is growing evidence that AKI is prevalent in COVID-19 patients and that SARS-CoV-2 specifically invades the kidneys.

Epidemiology {#Sec2}
============

In a case series of 116 non-critically ill Chinese patients from Wuhan, Wang L. et al. have found that only 12 (10.8%) experienced a small increase in serum creatinine or urea nitrogen within the first 48 h of hospital stay \[[@CR6]\]. However, this has been challenged by most recent findings. As shown in Table S1, AKI during hospital stay is reported with an average incidence of 11% (8--17%) overall, with highest ranges in the critically ill (23% (14--35%)) (Table S1, Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Of note, renal replacement therapy (RRT) was used in near 5% of the critically ill patients. These results have to be interpreted with caution. Indeed, the actual AKI incidence, in particular in ICU, remains uncertain and may have been underestimated due to the retrospective design of the studies and the lack of clear operational AKI definitions in most of the reports (Table S1). Of note, although several studies have used the Kidney Disease Improving Global Outcomes (KDIGO) definition \[[@CR4], [@CR6]--[@CR13]\], none of them have reported AKI stages. In our center, in a cohort of 99 critically ill patients with severe SARS-CoV-2 infection, 42 patients (42.9%) have developed AKI and among them 32 (74.4%) severe AKI (KDIGO stage III). RRT has been required in 13 patients (13.4%) (unpublished data). These discrepancies across studies could be explained by other factors such as race, patient characteristics (comorbidity, smoking), illness severity (inclusion of all clinical cases versus only laboratory-confirmed cases) and variation in local practice regarding fluid and hemodynamic management, ventilation strategy and medication use. These epidemiological findings should also be put into perspective with previous reports in other pandemic processes, such as H1N1 influenza, where similar incidences have been described.Fig. 1AKI incidence in hospitalized patients with COVID-19 infection. Forestplot showing incidence of AKI in patients with COVID-19 infection. The square indicates the proportion of patients in each study. The vertical dashed line indicates the population mean (all datasets combined) and the blue diamond the 95% CI around that meanFig. 2AKI incidence in ICU in patients with COVID-19 infection. Forestplot showing incidence of AKI in critically ill patients with COVID 19 infection. The square indicates the proportion of patients in each study. The vertical dashed line indicates the population mean (all datasets combined) and the blue diamond the 95% CI around that mean

The timeline of AKI onset is another issue. Only four studies reported AKI at hospital admission \[[@CR5], [@CR10], [@CR11], [@CR14]\], with an incidence ranging from 1% \[[@CR5]\] to 29% \[[@CR11]\] (Table S1). In most studies, AKI developed throughout hospital stay, with an average of 5 to 9 days after admission \[[@CR11], [@CR15], [@CR16]\]. AKI developed more frequently in patients with the most severe disease (in particular severe ARDS, requiring invasive mechanical ventilation), the older or those with comorbidities such as hypertension or diabetes \[[@CR8], [@CR17]\]. As shown in Table S1, these conditions are frequently encountered in patients admitted for severe SARS-CoV-2 infection.

AKI is a well-recognized factor of poor prognosis \[[@CR18]\]. In SARS-CoV-2 infection, five studies have found a significant association between kidney failure and death \[[@CR8], [@CR9], [@CR11], [@CR17], [@CR19]\]. Interestingly, Cheng et al. \[[@CR9]\] have found that only AKI stage 2 or higher was associated with a greater risk of mortality \[HR: 3.53 (1.5--8.27)\].

Urinalysis during SARS-CoV-2 infection {#Sec3}
======================================

In parallel to kidney dysfunction defined by an increased in serum creatinine, several studies have highlighted abnormalities in the urinary sediment.

Proteinuria and hematuria {#Sec4}
-------------------------

Proteinuria has been commonly observed during SARS-CoV-2 infection and is reported in 7 up to 63% of cases \[[@CR6], [@CR9], [@CR20], [@CR21]\]. Cheng et al. reported hematuria in 26.7% of the patients \[[@CR9]\]. Two phenotypes of proteinuria have been identified: Most of the time proteinuria is of low abundance, rated at 1 + on the urinary dipstick, probably reflecting tubular injury. In some cases, proteinuria is abundant or constituted with albumin suggesting glomerular impairment. Viral injury to podocytes but also RAAS activation may have contributed to proteinuria: Accumulation of angiotensin II may be responsible for nephrin endocytosis and subsequently increased glomerular permeability with proteinuria \[[@CR22]\]. Two cases of massive proteinuria associated with severe AKI and histological collapsing glomerulopathy were reported in 2 black patients hospitalized for SARS-CoV-2 infection \[[@CR23], [@CR24]\]. This form of glomerulopathy has been linked to a variety of conditions, including viral infections \[[@CR25]\]. Interestingly, both proteinuria and hematuria are strongly associated with an increased hospital mortality \[[@CR9]\].

These results should be interpreted with caution for several reasons. First, proteinuria was measured at admission without previous values available. Yet, patients included in these studies often exhibited risk factors for kidney impairment such as diabetes, high blood pressure and overweight. Secondly, the association with mortality may reflect the severity of SARS-CoV-2 infection but may also point to an advanced underlying patient condition. Third, especially in black patients, it cannot be excluded that the genetic APOL1 variant may have contributed to the pathogenesis of collapsing glomerulopathy. Finally, proteinuria and hematuria should be interpreted with caution in critically ill, febrile and oliguric patients, especially when determined by dipstick \[[@CR26]\].

Increased kaliuresis {#Sec5}
--------------------

In a cohort of 175 patients infected with COVID-19, hypokalemia with increased kaliuresis, as a marker of renin--angiotensin--aldosterone system (RAAS) activation, was associated with the most severe forms of SARS-CoV-2 infections requiring ICU admission. Indeed, 93% of patients hospitalized in ICU had hypokalemia at admission \[[@CR27]\]. The authors suggest that increased kaliuresis is related to increased angiotensin II levels. However, data with specific measurements of all components of RAAS will be needed to confirm this hypothesis. Indeed, hypokalemia may be secondary to SARS-CoV-2-induced diarrhea, the use of diuretics or other drug-induced tubulopathies.

Presence of SARS-CoV-2 in the urine {#Sec6}
-----------------------------------

Presence of SARS-CoV-2 has rarely been shown in the urine swabs of COVID-19 patients raising the possibility of a renal reservoir of SARS-CoV-2 (5,6,29). However, whether the presence of viral RNA in the urine swabs implies that the urine is contagious should be determined by testing for living virus.

Histopathological findings during acute kidney injury {#Sec7}
-----------------------------------------------------

Diao et al*.* first reported the postmortem analysis of kidney tissues of 6 patients who died from COVID-19 \[[@CR28]\]. More recently, Su et al*.* have analyzed kidney histopathological lesions in 26 patients who died from COVID-19 \[[@CR29]\]. Using light microscopy, immunohistochemistry and electron microscopy, they reported several abnormalities, including:Histopathological findings related to the underlying conditions of patients at risk for severe SARS-CoV-2 infection (diabetes, hypertension, cardiovascular diseases), such as nodular mesangial expanding and hyalinosis of arterioles in diabetic patients, arteriolosclerosis with ischemic glomeruli in patients with hypertension and/or cardiovascular diseases.Evidence of direct renal parenchyma infection: By light microscopy, Su et al. found diffuse acute proximal tubular injury with cytoplasmic vacuoles that may be related to direct viral infection in the proximal tubular epithelium. By transmission electron microscopy, virus particles were mainly identified in the cytoplasm of renal proximal tubular epithelium and in the podocytes, with secondary foot process effacement and detachment of podocytes from the glomerular basement membrane. By indirect fluorescence, tubular epithelium expressed SARS-CoV nucleoprotein in 3 patients \[[@CR29]\]. Kissling et al*.* reported a case of severe collapsing focal glomerulopathy with in the podocyte cytoplasm, vacuoles containing numerous spherical particles that had the typical appearance of viral inclusion bodies \[[@CR23]\]. Puelles et al*.* also detected a positive SARS-CoV-2 viral load in the autopsy of kidneys from COVID-19 patients, with preferential localization in glomeruli. Interestingly, multiple underlying conditions were associated with SARS-CoV-2 kidney tropism \[[@CR30]\]. Thus, these studies suggest direct invasion of SARS-CoV-2 into renal parenchyma.Another common morphologic finding was diffuse erythrocyte aggregation and obstruction in the lumen of glomerular and peritubular capillaries without platelets, red blood cell fragments, fibrin thrombi or fibrinoid necrosis.Glomerular ischemia and endothelial cell injury were also present in some cases. Su et al. found evidence of glomerular ischemia in 3 patients with fibrin thrombi within the glomerular capillary loops \[[@CR29]\], likely reflecting coagulation activation in COVID-19 patients \[[@CR16]\].Other histological findings include myoglobin casts or cellular debris casts. Rhabdomyolysis has also been reported in patients with COVID-19 \[[@CR31]\].Although lung injury during severe SARS-CoV-2 infection appears to be partially linked to complement activation \[[@CR32]\], there is no evidence of complement activation in the kidney \[[@CR33]\].

It is important to keep in mind that most of histological data stem from postmortem analysis. It is therefore difficult to conclude whether these histological lesions are direct consequences of the virus or of sepsis and/or multiple organ failure \[[@CR34]\]. More kidney biopsies of COVID-19 alive patients may help to answer this question.

Pathophysiology of acute kidney injury {#Sec8}
======================================

The pathophysiological understanding of COVID-19-related AKI is yet to be elucidated. Current knowledge suggests unspecific mechanisms, but also more COVID-19 specific mechanisms such as a direct viral injury via its receptor (ACE2) which is highly expressed in the kidney, an imbalanced RAAS, an elevation of pro-inflammatory cytokines elicited by the viral infection and microvascular thrombosis (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Mechanisms of acute kidney injury (AKI) during severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection. SARS-CoV-2 can penetrate proximal tubule cells by linking with ACE2 and CD147, as well as in the podocytes, by linking with ACE2. Virus entry may be responsible for podocyte dysfunction, leading to glomerular diseases such as focal segmental glomerulosclerosis (FSGS), and acute proximal tubular injury leading to tubular necrosis. SARS-CoV-2 is responsible for an imbalanced RAAS activation that promotes glomerular dysfunction, fibrosis, vasoconstriction and inflammation. SARS-CoV-2 infection also triggers coagulation activation, leading to kidney vascular injury such as ischemic glomeruli and fibrinoid necrosis. Glomerular capillaries obstruction by red blood cells has also been reported during SARS-CoV-2 infection. The elevation of cytokines induced by severe SARS-CoV-2 infection may also participate to the genesis of AKI. Finally, unspecific factors relative to intensive care unit (ICU) management may aggravate kidney injury. TNF-α, tumor necrosis factor alpha; IL-6, interleukine 6; IL-1β, interleukin 1; MCP1, monocyte chemoattractant protein 1; ACE2, angiotensin-converting enzyme 2; FSGS, focal segmental glomerulosclerosis; RAAS, renin--angiotensin--aldosterone system; PEEP, positive end-expiratory pressure; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ICU, intensive care unit

Unspecific mechanisms {#Sec9}
---------------------

Several factors may contribute to AKI onset, in particular in the critically ill \[[@CR35]\]. First, most COVID-19 patients with AKI are older and have frequent comorbidities such as hypertension or diabetes mellitus (Table S1) \[[@CR2], [@CR5], [@CR7]\]. These factors are well-known factors of renal vulnerability. Recently, they have been identified as contributors to AKI development in patients with acute respiratory failure \[[@CR36]\]. Moreover, due to these conditions, patients are frequently treated with drugs that interfere with regulation of renal flow, such as ACE inhibitors. This could be of importance, because a lot of patients experienced prolonged fever, tachypnea and gastro-intestinal troubles, which could lead to hypovolemia and subsequent pre-renal AKI \[[@CR5], [@CR7]\]. However, to date, no study reported specific data on volume status at the time of hospital admission and we can only assume the role of these factors in AKI onset \[[@CR37]\]. Nephrotoxicity may also be involved. Radiographic contrast media used to investigate thromboembolic events (pulmonary embolism in particular) may play a role in AKI onset. Nephrotoxic drugs can also be incriminated in AKI development, especially antibiotics, antiviral therapy or traditional medicine. However, these factors have been poorly investigated in COVID-19 patients.

Second, others mechanisms could contribute to AKI development in patients with acute respiratory distress syndrome (ARDS), which is the leading cause of admission in patients with severe SARS-CoV-2 infection \[[@CR2], [@CR5], [@CR7]\]. Impairment of gas exchange and severe hypoxemia has been recognized as factors associated with AKI in patients with ARDS \[[@CR38]\]. In a case series of 1591 patients admitted in ICU during the early stage of the outbreak in Lombardy, Grasselli et al. reported that severe hypoxemia (with a median PaO~2~/FiO~2~ at 160 \[114--220\] mmHg at ICU admission) is common. Hemodynamic disturbances such as central venous pressure elevation, increased intra-thoracic pressure or volume overload may also result in AKI initiation or aggravation \[[@CR39]\]. Although there is a low level of clinical evidence \[[@CR40]\], several physiological studies suggested that high intra-thoracic pressures and PEEP could influence urine output and glomerular filtration \[[@CR41], [@CR42]\].

Recently, Gattinoni et al*.* have argued that, in the early phase of COVID‑19 pneumonia, pulmonary mechanics may be different from traditional ARDS, with a phenotype (called Type-L in contrast to Type-H with more classical aspects) characterized by normal compliance, low lung recruitability and without need for very high PEEP or even deleterious effects of the latter \[[@CR43]\]. In other words, high and kidney-unfriendly levels of PEEP may not be required in the early phase of COVID-19 ARDS. Finally, inflammatory effects of invasive mechanical ventilation per se especially when a non-protective strategy is applied \[[@CR44]\] could also contribute to kidney injury \[[@CR45]\].

Entry of SARS-CoV-2 cells into the kidney {#Sec10}
-----------------------------------------

Angiotensin conversion enzyme 2 (ACE2) is a homolog of ACE that converts angiotensin II to angiotensin 1--7, which alleviates renin--angiotensin system-related vasoconstriction (Fig. [4](#Fig4){ref-type="fig"}). There are 2 forms of ACE2: soluble ACE2 and membrane-bound ACE2. SARS-CoV-2 binds with ACE2 on the cell membrane of the host cells. Cell entry of coronavirus depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Therefore, cell invasion depends on ACE2 expression and also the presence of the protease TMPRSS2 (Transmembrane protease, serine 2), that is able to cleave the viral spike \[[@CR46]\]. In the kidneys, ACE2 is expressed in the apical brush borders of the proximal tubules as well as the podocytes. In endothelial cells of the kidney, only ACE is expressed without detectable ACE2 \[[@CR47]\]. Recent human tissue RNA-sequencing data demonstrated that kidney expression of ACE2 was nearly 100-fold higher than in pulmonary tissue \[[@CR20]\]. TMPRSS2 has also been detected in the kidney \[[@CR48]\] and more specifically in the proximal tubules \[[@CR49]\]. More recently, Wang et al*.* found that SARS-CoV-2 invaded host cells via a novel route of CD147-spike protein \[[@CR50]\]. CD147 is ubiquitously expressed transmembrane glycoprotein and is highly expressed on proximal tubular epithelial cells and inflammatory cells and has been involved in various kidney diseases \[[@CR51]\].Fig. 4Role of ACE2 and renin--angiotensin--aldosterone system (RAAS) during SARS-CoV-2 infection. Angiotensinogen is converted into angiotensin I by renin and then into angiotensin II (also known as angiotensin (1--8)) by ACE. Angiotensin II, through its binding to AT1R, is responsible for the deleterious effects of RAAS activation (i.e., fibrosis, inflammation, vasoconstriction). ACE2 counteracts deleterious effects of RAAS activation by converting angiotensin I into angiotensin (1--9) and angiotensin II into angiotensin 1--7 that binds to Mas receptor and exerts anti-inflammatory and vasodilatory effects. SARS-CoV-2 binds to membrane-bound ACE2 and invades the cell membrane by endocytosis thus reducing levels of membrane-bound ACE2. Cell invasion depends on ACE2 expression and also on the presence of the protease TMPRSS2, that is able to cleave the viral spike. Diminution of ACE2 results in an accumulation of angiotensin II that is responsible for overactivation of RAAS, leading to increased inflammation, fibrosis, vasoconstriction. Circulating ACE2 could act as a decoy and bind to SARS-CoV-2, thereby preventing internalization of membrane-bound ACE2 by SARS-CoV-2. Under physiological conditions, ACE2 is linked to AT1R, forming a complex that prevents degradation of membrane-bound ACE2 through lysozome internalization. Angiotensin II links to AT1R and decreases the interaction between ACE2 and AT1R, inducing ubiquitination and internalization of ACE2. ARB may increase membrane-bound ACE2 availability by preventing its internalization. However, as the virus requires membrane-bound ACE2 internalization to penetrate the cell, ARB may also decrease the susceptibility to the virus by preventing from virus-ACE2 internalization. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RAAS, renin--angiotensin--aldosterone system; ACE, angiotensin-converting enzyme; ATII, angiotensin II; AT1R, angiotensin receptor type I; ACE2, angiotensin-converting enzyme 2; Mas-R, Mas receptor; ARB, angiotensin receptor blocker; TMPRSS2, transmembrane protease, serine 2

Imbalanced RAAS activation {#Sec11}
--------------------------

First, the SARS-CoV-2 attaches to ACE2 and induces a down-regulation of membrane-bound ACE2 that promotes accumulation of angiotensin II by reducing its degradation into angiotensin 1--7. Thus, COVID-19 mediated angiotensin II accumulation may promote an imbalanced RAAS activation, leading to inflammation, fibrosis, vasoconstriction \[[@CR52]\] (Fig. [4](#Fig4){ref-type="fig"}).

Secondly, ACE2 usually interacts with AT1 receptor, forming a complex that prevents internalization and degradation of membrane-bound ACE2 into lysosomes. Accumulation of angiotensin II decreases this interaction and induces ubiquitination and internalization of membrane-bound ACE2 into lysosomes \[[@CR53]\] (Fig. [4](#Fig4){ref-type="fig"}).

Role of RAAS inhibitors {#Sec12}
-----------------------

Because of the RAAS activation and the interaction between SARS-CoV-2 and ACE2, some authors have suggested RAAS inhibitors as potential treatments for COVID-19 infection \[[@CR54]\]. Conversely, other studies have suggested that ACE inhibitors and ARB may increase ACE2 expression and therefore increase the susceptibility of patients to SARS-CoV-2 infection \[[@CR55], [@CR56]\]. However, membrane-bound and circulating ACE2 may exert antagonist effects on COVID-19 invasiveness. Circulating ACE2 may act as a decoy by preventing SARS-CoV-2 entry into target cells which depends on its membrane-bound ACE2 receptor. This means that besides the ACE/ACE2 balance, the soluble ACE2/membrane-bound ACE2 balance is equally as important. The role of RAAS inhibitors should be then examined in light of its potential disruption of both of these equilibriums \[[@CR52]\]. Two recent retrospective studies have suggested that RAAS inhibitors could be protective in COVID-19 patients \[[@CR57], [@CR58]\]. In the first retrospective study including 1128 patients with hypertension, the authors observed a decreased risk of all-cause mortality in patients receiving ACE inhibitors/ARB \[[@CR57]\]. In the second study, a small retrospective cohort, RAAS inhibitor use was associated with a tendency to a lower proportion of critical patients and lower mortality rate \[[@CR58]\].

Recent clinical studies suggest the lack of association between RAAS inhibitors and the risk of COVID-19 or mortality \[[@CR59]--[@CR61]\]. To date, cardiovascular societies have therefore recommended against adding or stopping RAAS inhibitors.

Role of cytokines in COVID-associated AKI {#Sec13}
-----------------------------------------

There is accumulating evidence that severe COVID-19 patients have elevated level of inflammatory cytokines, especially when they are admitted to the ICU. Huang et *al.* showed that interleukin-1β (IL-1β), IL-1RA, IL-7, IL-8, IL-9, IL-10, fibroblast growth factor (FGF), granulocyte macrophage colony stimulating factor (GM-CSF), interferon-γ (IFNγ), granulocyte colony stimulating factor (G-CSF), interferon-γ-inducible protein (IP10), monocyte chemoattractant protein (MCP1), macrophage inflammatory protein 1 alpha (MIP1A), platelet-derived growth factor (PDGF), tumor necrosis factor (TNFα), vascular endothelial growth factor (VEGF) were increased, among which IL-2, IL-7, IL-10, G-CSF,IP10, MCP1, MIP1A, TNFα were higher in critically ill patients \[[@CR7]\]. These cytokines may participate to AKI in COVID-19 patients, by interacting with kidney resident cells and inducing endothelial and tubular dysfunction. For example, TNF-α can bind directly to tubular cell receptors, triggering the death receptor pathway of apoptosis \[[@CR62]\]. Other studies have also found an elevation of IL-6 in critically ill patients with COVID-19 with increased IL-6 levels in non-survival group of COVID-19 patients when compared to survivors \[[@CR16]\]. The deleterious role of IL-6 has been demonstrated in different models of AKI, including ischemic AKI, nephrotoxin-induced AKI and sepsis-induced AKI \[[@CR63], [@CR64]\]. In a model of nephrotoxin-induced AKI, TNFα^−/−^ mice and IL-6^−/−^ mice display relative resistance to AKI \[[@CR64]\]. IL-6 also induces an increased renal vascular permeability, the secretion of pro-inflammatory cytokine/chemokines by renal endothelial cells (IL-6, IL-8 and MCP-1), and may participate to microcirculatory dysfunction \[[@CR65]\]. Therefore, we can assume that these cytokines may participate to AKI in COVID-19 patients. However, elevation of cytokines is moderate (median IL-6 of 79 pg/ml (39--135 pg/ml) in our ICU cohort (unpublished data)) when compared to hyper-inflammatory ARDS (median IL-6 of 1568 pg/mL; 517-3205 pg/mL) \[[@CR66]\], sepsis (median IL-6 of 1346 pg/mL; 292-8789 pg/mL) \[[@CR67]\] or cytokine release syndrome where median interleukin-6 may approach 10000 pg/mL \[[@CR68]\]. Moreover, whether the elevation of cytokines in COVID-19 patients translates into a beneficial effect of immunomodulatory strategies is still unknown.

Role of thrombosis in COVID-associated AKI {#Sec14}
------------------------------------------

The high incidence of acute thrombotic events in COVID-19 patients has been reported by several authors, mainly venous thrombosis and pulmonary embolism \[[@CR69], [@CR70]\]. Helms et al. found that 16.7% of critically ill patients admitted for SARS-CoV-2 infection had pulmonary embolism. Interestingly, COVID-19 ARDS patients exhibited more thrombotic complications than non-COVID-19 ARDS patients \[[@CR70]\]. In the kidney, the presence of fibrin deposits in glomerular loops \[[@CR29]\] is in favor of a dysregulation of coagulation homeostasis that can participate to renal microcirculatory dysfunction and AKI. In a retrospective study, Tang et al. demonstrated that the use of prophylactic anticoagulant therapy was associated with decreased mortality in COVID-19 patients \[[@CR71]\]. However, no data are available on the impact of anticoagulant therapy on renal outcomes. High prevalence of pulmonary embolism during SARS-CoV-2 infection and subsequent right heart failure may also contribute to venous congestion and development of AKI \[[@CR72]\].

Treatment of COVID-19-induced AKI {#Sec15}
=================================

To date, there is no specific treatment for COVID-19-induced AKI. A number of investigational agents are being explored for treatment of COVID-19 \[[@CR73]\]. However, there are no controlled data supporting the use of any specific treatment (antiviral drugs or immunomodulatory drugs), and their efficacy for COVID-19 is still unknown. Concerning RRT, there are no data supporting the use of different strategies than those used in the context of sepsis. The timing of RRT, modality (intermittent versus continuous) and dose may therefore rely on non-COVID-19 data \[[@CR74]\]. Of note, Helms et al*.* found a high incidence of filter clotting during RRT (especially during continuous veno-venous hemofiltration, with up to 96.6% of filter clotting) \[[@CR70]\]. If possible, citrate regional anticoagulation (in addition to systemic anticoagulation) should then be preferred. If not, special attention should be paid to administer efficient heparin anticoagulation.

To date, there is no evidence for clinically important cytokine removal with RRT during sepsis-induced AKI and no data are available in the setting of COVID-19 \[[@CR75]\].

In case of persistent proteinuria or hematuria at ICU discharge, COVID-19 patients may benefit from follow-up by a nephrologist.

Conclusion {#Sec16}
==========

AKI is prevalent in critically ill COVID-19 patient. Kidney involvement is associated with poor outcomes. Several mechanisms are possibly involved in kidney injury during SARS-CoV-2 infection, including direct invasion of SARS-CoV-2 into the renal parenchyma, an imbalanced RAAS and microthrombosis but also kidney injury secondary to hemodynamic instability, inflammatory cytokines and the consequences of therapeutics that are used in ICU (nephrotoxic drugs, mechanical ventilation). Early detection and specific therapy of renal changes, including adequate hemodynamic support and avoidance of nephrotoxic drugs, may help to improve critically ill patients with COVID-19.
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